Restoration of T and NK cell function in GM-CSF mobilized stem cell products from breast cancer patients by monocyte depletion

Bone Marrow Transplantation

Volumn 20, Issue 2, 1997, Pages 117-123

  Ageitos, A G ^a   Ino, K ^a   Ozerol, I ^a   Tarantolo, S ^a   Heimann, D G ^a   Talmadge, J E ^a,b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Monocytes; NK; Suppression; T cell; Tolerance

Indexed keywords

CARBONYL IRON; CD14 ANTIGEN; CD3 ANTIGEN; CD8 ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3;

ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BREAST CANCER; CELL CULTURE; CELL FUNCTION; CELL ISOLATION; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LYMPHOCYTE PROLIFERATION; LYMPHOID CELL; MITOGENESIS; MONOCYTE; NATURAL KILLER CELL; PERIPHERAL BLOOD STEM CELL; PHAGOCYTE; PRIORITY JOURNAL; STEM CELL; STEM CELL TRANSPLANTATION; T LYMPHOCYTE;

EID: 0030841819     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1700864     Document Type: Article

References (44)

1. Hryniuk W, Levine MN. Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol 1986; 4: 1162-1170.
2. Bezwoda, WR, Seymour L, Dansey RD. High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial. J Clin Oncol 1995; 13: 2483-2489.
3. Liberti G, Pearce R, Taghipour G et al. Comparison of peripheral blood stem-cell and autologous bone marrow transplantation for lymphoma patients: a case-controlled analysis of the EBMT Registry data. Ann Oncol 1994; 5: 5151-5153.
4. Kessinger A. Is blood or bone marrow better? Stem Cells 1993; 11: 290-295.
5. Vose JM, Anderson JR, Kessinger A et al. High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphoma. J Clin Oncol 1993; 11: 1846-1851.
6. Freedman AS, Nadler LM. Which patients with relapsed non-Hodgkin's lymphoma benefit from high-dose therapy and hematopoietic stem-cell transplantation? J Clin Oncol 1993; 11: 1841-1843.
7. Talmadge JE, Reed EC, Kessinger A et al. Immunologic attributes of cytokine mobilized peripheral blood stem cells and recovery following transplantation. Bone Marrow Transplant 1996; 17: 101-109.
8. Talmadge TE, Reed EC, Ino K et al. Rapid immunologic reconstitution following transplantation with mobilized peripheral blood stem cells as compared to bone marrow. Bone Marrow Transplant 1997; 19: 161-172.
9. Henon PR, Liang H, Beck-Wirth G et al. Comparison of hematopoietic and immune recovery after autologous bone marrow or blood stem cell transplants. Bone Marrow Transplant 1992; 9: 285-291.
10. Roberts MM, To LB, Gillis D et al. Immune reconstitution following peripheral blood stem cell transplantation, autologous hone marrow transplantation and allogeneic bone marrow transplantation. Bone Marrow Transplant 1993; 12: 469-475.
11. Kiesel S, Pezzutto A, Moldenhaur G et al. B-cell proliferative and differentiative responses after autologous peripheral blood stem cell or bone marrow transplantation. Blood 1988; 72: 672-678.
12. Mills KC, Gross TG, Varney ML et al. Immunologic phenotype and function in human bone marrow, blood stem cells and umbilical cord blood. Bone Marrow Transplant 1996; 18: 1-6.
13. Verbik DJ, Jackson JD, Pirruccello SJ et al. Functional and phenotypic characterization of human peripheral blood stem cell harvests: a comparative analysis of cells from consecutive collections. Blood 1995; 85: 1964-1970.
14. Palathumpat V, Dejbakhsh-Jones S, Holm B et al. Different subsets of T cells in the adult mouse bone marrow and spleen induce or suppress acute graft-versus-host disease. J Immunol 1992; 149: 808-817.
15. Mortari F, Singhal SK. Production of human bone marrow-derived suppressor factor. Effect on antibody synthesis and lectin-activated cell proliferation. J Immunol 1988; 141: 3037-3042.
16. Mortari F, Bains MA, Singhal S. Immunoregulatory activity of human bone marrow identification of suppressor cells possessing OKM-1, SSEA-1, and HNK-I antigens. J Immunol 1986; 137: 1133-1137.
17. Moore SC, Theus SA, Barnett JB, Soderberg LS. Cytokine regulation of bone marrow natural suppressor cell activity in the suppression of lymphocyte function. Cell Immunol 1992; 141: 398-408.
18. Schreiber KL, Forman J. Effects of bone marrow-derived natural suppressor activity on B cell responses to lipopolysaccharide. Transplantation 1993; 56: 700-708.
19. Soderberg LSF. Differential activities of rabbit bone marrow suppressor cells. Int Arch Aller Appl Immunol 1984; 74: 341-346.
20. Wallis RS, Fujiwara H, Ellner JJ. Direct stimulation of monocyte release of interleukin-1 by mycobacterial protein antigens. J Immunol 1986; 136: 193-196.
21. Maes LY, York JL, Soderberg LS. A soluble factor produced by bone marrow natural suppressor cells blocks interleukin-2 production and activity. Cell Immunol 1988; 116: 35-43.
22. Munn DH, Pressey J, Beall AC et al. Selective activation-induced apoptosis of peripheral T cells imposed by macrophages: a potential mechanism of antigen-specific peripheral lymphocyte deletion. J Immunol 1996; 156: 523-532.
23. Wu MX, Daley JF, Rasmussen RA, Schlossman SF. Monocytes are required to prime peripheral blood T cells to undergo apoptosis. Proc Natl Acad Sci USA 1995; 92: 1525-1529.
24. Wu MX, Ao Z, Hegen M et al. Requirement of fas (CD95), CD45, and CD11a/CD18 in monocyte-dependent apoptosis of human T cells. J Immunol 1996; 57: 707-713.
25. Ino K, Singh RK, Talmadge JE. Monocytes from mobilized stem cell products induce T cell apoptosis. J Leuk Biol 1997; 61: 583-591.
26. Dennis MW. Ingestion of carbonyl iron. In: Herscowitz HB, Holden HT, Bellanti JA, Ghaffar A (eds). Manual of Macrophage Methodology, Collection, Characterization and Function. Mercel Dekker: New York, 1981, pp 105-111.
27. Wang SY, Su CY, Hsu ML et al. Effect of lipopolysaccharide on the production of colony-stimulating factors by the stromal cells in long-term bone marrow culture. Exp Hematol 1991; 19: 122-127.
28. Holtrop S, Rijke-Schilder GPM, Tamboer WPM et al. Removal of monocytes from cell suspension with anti-CD14 antibody and carbonyl-iron using FC-gamma-dependent accessory function as a sensitive measure of monocyte presence. J Immunol Meth 1992; 156: 217-222.
29. Young MR, Newby M, Wepsic HT. Hematopoiesis and suppressor bone marrow cells in mice bearing large metastatic Lewis lung carcinoma tumors. Cancer Res 1987; 47: 100-105.
30. Noga SJ, Wagner JE, Horwitz LR et al. Characterization of natural suppressor cell populations in adult rat bone marrow. J Leuk Biol 1988; 43: 279-287.
31. Piguet PF, Irle C, Vassalli P. Immunosuppressor cells from newborn mouse spleen are macrophages differentiating in vitro from monoblastic precursors. Eur J Immunol 1981; 11: 56-61.
32. Mills CD. Molecular basis of 'suppressor' macrophages. Arginine metabolism via the nitric oxide synthetase pathway. J Immunol 1991; 146: 2719-2723.
33. Weiss A, Fitch FW. Macrophages suppress CTL generation in rat mixed leukocyte cultures. J Immunol 1977; 119: 510-516.
34. Oehler JR, Herberman RB, Campbell DA, Djeu JY. Inhibition of rat mixed lymphocyte cultures by suppressor macrophages. Cell Immunol 1977; 29: 238-250.
35. Hibbs JB, Vavrin Z, Taintor RR. L-Arginine is required for expression of the activated macrophage effector mechanism causing selective metabolic inhibition in target cells. J Immunol 1987; 138: 550-565.
36. Kono K, Salazar-Onfray F, Petersson M et al. Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing zeta molecules and inhibits tumor-specific T cell and natural killer cell-mediated cytotoxicity. Eur J Immunol 1996; 26: 1308-1313.
37. Kaempfer R. Regulation of the human interleukin-2/interleukin-2 receptor system: a role for immunosuppression. Proc Soc Exp Biol Med 1994; 206: 176-180.
38. Kessinger A, Armitage JO. The evolving role of autologous peripheral stem cell transplantation following high-dose therapy for malignancies. Blood 1991; 77: 211-213.
39. Benyunes M, Massumoto C, Higuchi CM. Interleukin-2 + lymphokine-activated killer cells as consolidative immunotherapy after autologous bone marrow transplantation for acute myelogenous leukemia: a preliminary report. Bone Marrow Transplant 1993; 12: 159-163.
40. Blaised D, Olive D, Stoppa AM. Hematologic and immunologic effects of the systemic administration of recombinant interleukin-2 after autologous bone marrow transplantation. Blood 1990; 76: 1092-1097.
41. Klingemann HG. Introducing graft-versus-leukemia into autologous stem cell transplantation. J Hematother 1995; 4: 261-267.
42. Arbour S, Toupin S, Belanger R et al. Phenotypic and functional characterization of peripheral blood and bone marrow natural killer cells prior to autologous transplantation. Bone Marrow Transplant 1996; 17: 315-322.
43. Neubauer MA, Benyunes MC, Thompson JA et al. Lymphokine-activated killer (LAK) precursor cell activity is present in infused peripheral blood stem cells and in the blood after autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 1994; 13: 311-316.
44. Robertson MJ, Ritz J. Biology and clinical relevance of human natural killer cells. Blood 1990; 76: 2421-2438.